Hologic (HOLX) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $1.03 per share a year ago.
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic Announces Financial Results for Second Quarter of Fiscal 2025.
The first-quarter 2025 earnings season is underway, with a number of top MedTech companies already releasing their numbers. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some
HOLX's second-quarter fiscal 2025 performance is likely to have benefited from expanding breast health offerings.
Molecular Diagnostics is likely to have aided HOLX's performance in the second quarter of fiscal 2025.
Dublin, April 25, 2025 (GLOBE NEWSWIRE) -- The "Cellulite Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #AI--Groundbreaking New Data on Hologic's AI-Powered Mammography Technology to Be Presented at SBI.
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In recent times, investors have been increasingly drawn to companies operating in the molecular diagnostics space, a rapidly growing segment within the broader in-vitro diagnostics (IVD) market. Accor
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--Hologic Details Environmental, Social and Governance Efforts — Including Expanded Environmental Ambitions — in New Sustainability Report.
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hologic (HOLX) concluded the recent trading session at $61.27, signifying a +0.67% move from its prior day's close.
HOLX's diagnostics strength, robust international potential and new board addition support its "Hold" case. Yet, ongoing global uncertainties remain a drag.
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #governance--Wayde McMillan Elected to Hologic Board of Directors.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE